➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Baxter
Dow
Johnson and Johnson
Boehringer Ingelheim

Last Updated: July 4, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Human secretin


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Human secretin?

Human secretin is an investigational drug.

There have been 18 clinical trials for Human secretin. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2017.

The most common disease conditions in clinical trials are Pancreatitis, Pancreatic Neoplasms, and Pancreatitis, Chronic. The leading clinical trial sponsors are ChiRhoClin, Inc., Repligen Corporation, and Massachusetts General Hospital.

There are six US patents protecting this investigational drug and forty-nine international patents.

Recent Clinical Trials for Human secretin
TitleSponsorPhase
Recurrent Abdominal Pain and Exocrine Pancreatic InsufficiencyChiRhoClin, Inc.Phase 3
Recurrent Abdominal Pain and Exocrine Pancreatic InsufficiencyOrlando Health, Inc.Phase 3
Secretin for Acute PancreatitisDartmouth-Hitchcock Medical CenterPhase 2

See all Human secretin clinical trials

Clinical Trial Summary for Human secretin

Top disease conditions for Human secretin
Top clinical trial sponsors for Human secretin

See all Human secretin clinical trials

US Patents for Human secretin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Human secretin   Start Trial Method for use of magnetic resonance imaging to image pancreas using secretin Wayne State University (Detroit, MI)   Start Trial
Human secretin   Start Trial Method for assisting in differential diagnosis and treatment of autistic syndromes Repligen Corporation (Waltham, MA)   Start Trial
Human secretin   Start Trial Use of secretin-receptor ligands in treatment of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) Pharmagene Laboratories Ltd. (Hertfordshire, GB)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Baxter
Dow
McKinsey
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.